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CASE PRESENTATION
A 50-year-old white man was referred to the hypertension clinic at the
Miami VA Medical Center for better control of hypertension. The patient
had had hypertension for 8 years, during which time he had followed a
number of different medical regimens. During the past year, he had taken
hydrochlorothiazide, 25 mg daily; atenolol, 50 mg daily; and hydralazine,
50 mg three times daily. He was examined in the emergency room one
week prior to being evaluated at the hypertension clinic. At that time, his
chief complaints were left facial weakness, and numbness and decreased
control of his left hand. The latter had lasted for about 20 minutes but had
disappeared by the time he was seen. A CT scan of the brain was normal,
and a transient ischemic attack (TIA) was diagnosed. His supine blood
pressure was 170/114 mm Hg and 166/112 mm Hg on two occasions. The
patient admitted having failed to take his hypertensive medications for the
previous 10 days; these were reinstituted. An appointment was made for
the neurology clinic the next day. While in the neurology clinic, a carotid
Doppler study revealed bilateral carotid artery plaques, but no ulcerative
lesions. His blood pressure was 168/94 mm Hg sitting. Therapy with one
aspirin per day was begun and he was referred to the hypertension clinic.
When seen in the hypertension clinic, the patient gave no history of
additional TIA episodes or other symptoms. The patient reported no
other medical problems other than having been told by a physician at his
workplace that his cholesterol was “a little elevated” and that his blood
sugar was “somewhat high but did not need to be treated medically.” He
had a 40-pack-year smoking history. Ethanol intake was limited to 2 beers
on weekends; coffee intake was 4 to 5 cups daily. The patient’s diet was
geared towards “meat and potatoes.” He was involved in some physical
activity at work (walking and lifting) but had exercised very little outside
of work. His father had died at age 56 of a myocardial infarction and his
mother at age 67 of a massive stroke. She also was known to have been
hypertensive during her last 15 years. A maternal uncle and a sister, aged
49, had type-II diabetes mellitus; two of his grandparents had died of
strokes.
Physical examination revealed a large man (height, 74 inches; weight,
252 pounds) with primarily android obesity. He was alert and oriented and
had no neurologic residua. Blood pressure was 164/104 mm Hg supine and
160/100 mm Hg standing. Funduscopic examination revealed grade-II
Keith-Wagener changes. Cardiac examination disclosed an S4 gallop. The
point of maximal impulse was 2 cm to the left of the midclavicular line and
sustained. His lungs were clear to auscultation and percussion. Abdominal
examination disclosed obesity, without organomegaly or bruits. The
extremities showed decreased popliteal and absent dorsalis pedis and
posterior tibialis pulses bilaterally.
Laboratory evaluation disclosed an electrocardiogram with sinus
rhythm and voltage criteria for left-ventricular hypertrophy; the heart rate
was 68 beats/min. A chest radiograph was normal. Other relevant labora-
tory data included: serum creatinine, 1.4 mg/dl; serum potassium, 5.1
mEq/liter; fasting blood glucose, 204 mg/dl; glycosylated hemoglobin,
10%; total cholesterol, 267 mg/dl; HDL cholesterol, 27 mg/dl; and
triglycerides, 192 mg/dl. Urine sediment examination was unremarkable,
and the urine protein was 21. Quantitation of urinary protein excretion
disclosed 640 mg/24 hrs. Ultrasonographic examination disclosed slight
renal asymmetry, and a nuclear scan revealed symmetric but modestly
diminished renal perfusion.
A clinical diagnosis of diabetic nephropathy was made, and captopril
was started at a dose of 12.5 mg orally every 12 hours. Subsequent
laboratory tests revealed an increase of the serum potassium to 6.2
mEq/liter and of the serum creatinine to 1.8 mg/dl. The ACE inhibitor was
discontinued with a subsequent return of serum creatinine and serum
potassium to previous levels. The blood pressure then was controlled with
amlodipine, 10 mg/day; the serum creatinine remained stable.
DISCUSSION
DR. MURRAY EPSTEIN (Professor of Medicine, University of
Miami School of Medicine, Miami, Florida, USA): The case
before us today raises a number of important clinical issues
regarding the management of patients with diabetes and
hypertension. These include instituting rational once-daily
dosing of antihypertensive agents to enhance compliance,
attaining goal blood pressure in an attempt to attenuate
progression of target organ disease, and selecting antihy-
pertensive agents that maintain rather than worsen meta-
bolic neutrality (for example, hypokalemia, hyperglycemia)
and do not exacerbate dyslipidemia. Today, however, I will
focus on one major issue—the role of calcium antagonists
in the management of patients with diabetes mellitus and
hypertension. I also will address a related important issue—
whether calcium antagonists retard progression of renal
disease. These issues are no longer theoretical consider-
ations; we now know that reducing blood pressure to
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appropriate levels in diabetic patients with hypertension
may require the concomitant use of several different anti-
hypertensive agents [1, 2].
Before reviewing these points, however, I will discuss our
current state of knowledge regarding the effects of calcium
antagonists on renal function and hemodynamics. I then
will review the available data regarding calcium antago-
nists’ influence on the progression of renal failure in both
nondiabetic renal disease and diabetic nephropathy.
In considering the effects of calcium antagonists, clini-
cians focus their attention primarily on the beneficial
effects in the management of symptomatic coronary artery
disease and on the ability to lower blood pressure. But
calcium antagonists also have important effects on renal
hemodynamics and renal function. More than 25 years ago,
Klutsch et al reported that nifedipine increased renal
perfusion and GFR in a group of patients with essential
hypertension [3]. Further, they systematically investigated
the effects of nifedipine in a large group of patients with
hypertension accompanied by varying degrees of renal
functional impairment. They observed that hypertensive
patients with the highest basal inulin clearance manifested
marked augmentation of renal hemodynamics, as assessed
by increments in inulin and para-aminohippurate clear-
ances. In contrast, hypertensive patients with impaired
renal function failed to manifest a renal vasodilatory re-
sponse to nifedipine (Fig. 1). Presumably the group (with
normal renal function) that responded to the calcium
antagonists exhibited a greater renal vasodilatory capacity
than did the group with impaired renal function, in whom
the decrement in renal perfusion might have been attrib-
utable to a “fixed” organic lesion.
Several subsequent reports have confirmed that, in con-
trast to the lack of hemodynamic effect in normal subjects,
hypertensive subjects exhibit an exaggerated renal hemody-
namic response to calcium antagonists [4], with sustained
increases in glomerular filtration rate (GFR) and renal
plasma flow (RPF) [4].
A similar exaggerated vasodilatory response has been
demonstrated in normotensive offspring of hypertensive
parents [5, 6]. Blackshear et al reported that at least 50% of
normotensive subjects with a family history of hypertension
exhibited an exaggerated renal vasodilatory response to
diltiazem, a response suggesting an inherited abnormality
of the renal vascular bed associated with hypertension.
Montanari and coworkers subsequently have confirmed
and extended these observations [6].
Aside from their effects on overall renal hemodynamics,
calcium antagonists induce substantive changes in the renal
microcirculation. Over the past decade several laboratories
have succeeded in characterizing the renal microcirculatory
profile of calcium antagonists. These studies have utilized
several innovative techniques and experimental models
including isolated microvessels, blood-perfused juxtamed-
ullary nephrons, in-vivo hydronephrotic kidneys, and iso-
lated perfused hydronephrotic kidneys (Table 1) [7–18].
Collectively, these direct in-vivo and in-vitro observations
in diverse experimental models indicate that calcium an-
tagonists antagonize preglomerular vasoconstriction, re-
sulting in afferent arteriolar vasodilation. In contrast, most
studies suggest that the efferent arteriole is refractory to
the vasodilatory effect of these agents [17–20]. This same
renal microcirculatory profile is found regardless of
whether vasoconstriction had been produced by endothe-
lin, norepinephrine, angiotensin II, KCl depolarization, or
thromboxane mimetics such as U44069. Most dihydropyri-
dines and the benzothiazepine diltiazem also have mani-
fested a similar renal microcirculatory profile [18, 19]. By
contrast, recent studies have suggested that several of the
Fig. 1. Effects of intravenous nifedipine (1 mg) on systolic and diastolic
blood pressure and para-aminohippurate (PAH) clearance in 9 patients
with essential hypertension (---) and 11 patients with hypertension and
renal functional impairment (—). Nifedipine significantly increased
PAH clearance in patients with essential hypertension. In contrast, “renal”
hypertensive patients failed to augment PAH clearance despite similar
blood pressure reduction. (From Ref. 3 with permission.)
Table 1. Methodology for assessing the renal microcirculationa
Methods Reference Characteristics
Indirect Micropuncture
Laser Doppler
Direct Isolated microvessels 7, 8 Without glomerulus
7–10 With glomerulus
Juxtamedullary nephron 11 Blood-perfused
Needle CCD 12 Intravital
Hydronephrotic kidney 13 In vivo
14–18 In vitro
a Adapted with permission from Ref. 18.
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newer calcium antagonists differ in their renal microcircu-
latory profile and are more favorable to the kidney [18].
Thus, efonidipine dilated virtually equally the afferent and
efferent arterioles (Fig. 2). Further, Tojo et al character-
ized the effects of manidipine hydrochloride on the renal
microcirculation in SHR rats using classic micropuncture
techniques [21]. Studies conducted after two months of
manidipine administration did not change single-nephron
GFR but increased single-nephron glomerular plasma flow.
Glomerular transcapillary hydraulic pressure difference
(DP), assumed to be the parameter most related to devel-
opment of glomerulosclerosis, fell significantly; both affer-
ent and efferent arteriolar resistances (RA and RE) de-
clined. Consequently, drugs such as manidipine and
efonidipine might be desirable antihypertensive agents for
patients with renal diseases because their renal microcircu-
latory profile theoretically would favor retarding progres-
sion of renal disease.
A large body of evidence indicates that, in addition to
their renal hemodynamic effects, calcium antagonists are
natriuretic in specific clinical settings [22–24]. Following
initiation of calcium antagonist therapy, sodium excretion
increases significantly on the first and second day, inducing
a negative sodium balance that averages 80 mEq over the
first 5 days [22, 23]. The natriuresis is highly variable and
occurs independently of the hypotensive response. After
the first or second day of treatment, a number of compen-
satory adjustments are activated, so that daily sodium
balance thereafter returns to zero. Nevertheless, the nega-
tive sodium balance established initially appears to be
sustained over the long term [23, 24].
Therapeutic strategies for preventing progressive renal
failure by treating hypertension
The consensus of most experts in the field, including the
Working Group on Hypertension and Chronic Renal Fail-
ure of the National High Blood Pressure Education Pro-
gram, is that the most important strategy for protecting the
kidney from hypertensive damage is effective control of
blood pressure [25, 26]. In addition to the compelling
importance of blood pressure reduction per se, increasing
evidence indicates that some classes of antihypertensive
Fig. 2. The effects of various calcium
antagonists on norepinephrine-induced
constriction of renal microvessels. Nifedipine,
nicardipine, and amlodipine elicited
predominantly afferent arteriolar vasodilation.
In contrast, efonidipine dilated both afferent
and efferent arterioles in a dose-dependent
manner. (Adapted with permission from Ref.
18.)
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medications confer a greater effect than others in slowing
progression of renal disease despite similar reductions in
systemic blood pressure. A substantive body of experimen-
tal studies has provided a theoretic framework suggesting
that ACE inhibition retards the progression of renal dis-
ease [27–32].
Studies over the past 15 years have demonstrated that
the sustained increase in glomerular capillary pressure
evoked in response to loss of renal mass produces a
destructive sclerosing reaction [27–30]. Administration of
ACE inhibitors countervails the effects of angiotensin II on
the renal microvasculature, decreasing glomerular capillary
pressure and reducing glomerular sclerosis. These findings
indicate that ACE-inhibitor therapy protects the injured
kidney from hemodynamically mediated glomerular dam-
age [31, 32]. The ACE inhibitors also might confer their
beneficial effects by modulating events independent of
their ability to ameliorate glomerular hypertension [33, 34].
These effects are summarized in several recent reviews
[35–37] and have been considered in a recent Nephrology
Forum [38].
Subsequently a number of clinical trials have investigated
the renal protective effects of ACE inhibitors in patients
with diabetes, and more recently in those with nondiabetic
renal disease [39–42]. The largest and most compelling of
these trials was conducted by the Diabetes Collaborative
Study Group [39]. Collectively, these studies have validated
the predictions from the earlier experimental models.
Calcium antagonists: Can they retard progression of
renal insufficiency?
As noted previously, calcium antagonists preferentially
block preglomerular vasoconstriction. However, inferences
from micropuncture studies on the effects of calcium
antagonists on preglomerular resistance in experimental
renal disease conflict. Table 2 summarizes the results from
studies in diverse renal injury models [43–46]. These
divergent observations in remnant kidney models, hemine-
phrectomized SHR, and heminephrectomized DOCA-
treated rats suggest that calcium antagonists have variable
effects on afferent and efferent arteriolar resistance and
glomerular hypertension in different experimental models.
Theoretically, preferential afferent vasodilation should
not reduce intraglomerular hypertension. However, cal-
cium antagonists have additional properties that may con-
tribute to their ability to protect the kidney under diverse
experimental conditions and perhaps in clinical disorders
[47–49]. Some of the more prominent mechanisms postu-
lated to mediate the renal protective actions of calcium
antagonists are listed in Table 3. These include the ability
of calcium antagonists to lessen injury by retarding renal
growth [50–52], to attenuate mesangial entrapment of
macromolecules [53, 54], to countervail or attenuate the
mitogenic effect of diverse cytokines and growth factors,
including platelet-derived growth factor and platelet-acti-
vating factor [53], and possibly to act as free-radical scav-
engers [49, 53].
Several studies suggest that calcium antagonists can
protect the kidney after reduction of renal mass. Dworkin
and Benstein have postulated that, in great part, glomeru-
lar injury depends not solely on the pressure developed
within the glomerular capillary, but also on the tension in
the vessel wall [55]. Tension appears to be influenced
equally by glomerular pressure (PGC) and vessel radius
(RGC). Thus, if the glomerular capillary radius increases
when kidneys hypertrophy, wall tension rises on both a
hemodynamic and a structural basis. Conversely, therapies
Table 3. Known and postulated mechanisms mediating the renal
protective actions of calcium antagonistsa
Reduction in systemic blood pressure
Reduction in renal hypertrophy
Modulation of mesangial traffic of macromolecules
Reduction in metabolic activity of remnant kidneys
Amelioration of uremic nephrocalcinosis
Attenuation of mitogenic effects of growth factors
Blockade of pressure-induced calcium entry
Decreased free radical formation
a Modified with permission from Ref. 47.
Table 2. Effects of calcium antagonists on renal microcirculation in various types of renal injury models
APa
(mm Hg)
RA RE
(dyne/sec/cm25 3 1010)
PGC
(mm Hg)
DP
(mm Hg) Ref.
5/6 Nx Control 154 6 6 1.20 6 0.20 0.80 6 0.10 68 6 3 51 6 3 43
Diltiazem 102 6 2* 1.10 6 0.20 0.70 6 0.20 50 6 2* 35 6 3*
SHR-UniNx Control 172 6 4 1.97 6 0.26 1.10 6 0.12 67 6 2 55 6 2 45
Nifedipine 126 6 3* 1.00 6 0.11* 0.73 6 0.06 60 6 1 45 6 1*
DOCA-UniNx Control 139 6 4 1.41 6 0.19 0.94 6 0.14 60 6 1 49 6 2 46
Nifedipine 106 6 2* 0.83 6 0.08* 0.97 6 0.08 62 6 2 49 6 1
DM-UniNx Control 118 6 5 0.80 6 0.10 0.70 6 0.10 60 6 1 47 6 1 44
Nifedipine 106 6 2* 0.60 6 0.10 0.60 6 0.10 60 6 2 45 6 2
a AP 5 arterial pressure, SHR 5 spontaneously hypertensive rat, Nx 5 nephrectomized, UniNx 5 uninephrectomized, DOCA 5 deoxycorticosterone
acetate, RA 5 afferent resistance, RE 5 efferent resistance, PGC 5 glomerular capillary pressure, DP 5 PGC - PBS, where PBS is hydraulic pressure in
Bowman’s space. * indicates P , 0.05 vs. control. Reproduced with permission from Ref. 18.
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that prevent hypertrophy could decrease tension by reduc-
ing RGC. Extending this hypothesis, Dworkin and col-
leagues have demonstrated that both enalapril and nifedi-
pine reduce blood pressure, lessen proteinuria, and
preserve glomerular architecture in a renal ablation model
[56]. They reported that RGC was significantly increased in
rats 8 weeks after 5⁄6 nephrectomy. Chronic administration
of the dihydropyridine nifedipine in doses chosen to nor-
malize systemic blood pressure reduced hypertrophy as
measured by kidney weight, glomerular capillary radius,
and glomerular volume. Because nifedipine reduced glo-
merular injury without lowering glomerular pressure, the
investigators postulated that the reduction in RGC was
sufficient to cause a decline in tension similar in magnitude
to that produced by agents such as ACE inhibitors, which
prevent injury by reducing PGC.
Subsequent studies attempting to test this hypothesis
with a different calcium antagonist using similar experi-
mental models have yielded inconsistent results. Dworkin
et al investigated the effects of amlodipine on glomerular
injury in two models of progressive renal failure—the
DOCA-salt-treated hypertensive rat and the uninephrecto-
mized SHR [57]. In contrast to the beneficial effects
observed previously with nifedipine administration [56],
amlodipine therapy failed to prevent glomerular injury.
Although systemic blood pressure was significantly reduced
in both models, amlodipine failed to reduce glomerular tuft
volume and did not lessen glomerular injury. The reasons
for these disparate results are not yet known.
An additional renal protective mechanism might relate
to the possibility that calcium antagonists attenuate mes-
angial entrapment of macromolecules. Thus, angiotensin II
has been demonstrated to influence the transport of blood-
borne macromolecules into the mesangium [58]. More than
a decade ago, Raij and Keane demonstrated that angioten-
sin II, when given to rats in subpressor doses, can both
increase the uptake and decrease the disappearance rate of
macromolecules such as radiolabeled IgG in the mesan-
gium [54]. Entrapment of macromolecules in the mesan-
gium can produce mesangial injury due to stimulation of
local inflammation and ultimately to expansion of mesan-
gial cell and/or matrix with subsequent progression to
glomerular sclerosis [54, 58]. The proposal that calcium
antagonists can counteract these mesangial effects of an-
giotensin II suggests an additional mechanism whereby
they might attenuate or retard the development of glomer-
ulosclerosis [49]. Calcium antagonists also might act by
modulating the mitogenic effects of diverse cytokines and
growth factors, including platelet activating factor (PAF)
and platelet-derived growth factor (PDGF) [59]. Nifedi-
pine, verapamil, and diltiazem have each been shown to
inhibit the mitogenic effect of PDGF and thrombin on
mesangial cells [60]. Subsequent studies have shown that
the calcium antagonist amlodipine inhibits proliferation of
human mesangial cells as well as protein synthesis and
therefore hypertrophy [61]. Calcium antagonists also in-
hibit thrombin-induced stimulation of PAF production by
endothelial cells; as a result, they can limit PAF-induced
glomerular injury [62].
Yet another mechanism by which calcium antagonists
might exert their protective effects includes amelioration of
mitochondrial calcium overload, which leads to mitochon-
drial malfunction and eventually cell death [63, 64]. Indeed,
calcium antagonists increase survival of ischemic tubular
cells in culture [65].
The available data on the ability of calcium antagonists
to retard progressive renal failure in experimental animals
conflict. Several studies suggest that calcium antagonists
are protective [66, 67]; others have failed to find such an
effect. Goligorsky et al investigated the effect of chronic
verapamil administration in experimental chronic renal
failure and concluded that chronic verapamil administra-
tion ameliorates uremic nephrocalcinosis [67]. Subse-
quently, Harris and coworkers investigated the effects of
long-term administration of verapamil on the progression
of experimental chronic renal failure in the rat [66]. The
indices studied included the degree of renal functional
deterioration, the extent of histologic damage and nephro-
calcinosis, and cumulative survival. These investigators
concluded that verapamil protects against renal dysfunc-
tion, histologic damage, nephrocalcinosis, and myocardial
calcification, and that it improves survival in the remnant
model.
Mu¨nter et al compared the renoprotective effects of
three interventions, the ACE inhibitor trandolapril, the
calcium antagonist verapamil, and the combination of the
two, on progression to glomerular sclerosis in adult, stroke-
prone, spontaneously hypertensive rats (SHRSP) [68]. Be-
cause blood pressure reduction alone might attenuate renal
damage, the doses of the antihypertensive drugs used were
selected deliberately to not lower blood pressure. Mono-
therapy with either verapamil (20 mg/kg/day) or trandola-
pril (0.03 mg/kg/day) reduced proteinuria but did not
change renal morphology. In contrast, treatment with the
combination of these two agents favorably affected renal
morphology. Despite persistence of the hypertension over
the entire 11-week period of observation, combined treat-
ment with trandolapril and verapamil retarded the progres-
sion to glomerular sclerosis and blunted the anticipated rise
in proteinuria. Only minimal histologic alterations were
observed, and the mean severity score of glomerular find-
ings was significantly lower than that of the control animals.
Furthermore, creatinine clearance was improved. The au-
thors concluded that the combination of low doses of an
ACE inhibitor and a calcium antagonist affords renal
protection independent of blood pressure lowering. Addi-
tional studies are required to further substantiate and
extend these promising results.
Another experimental model used to assess the renopro-
tective effects of calcium antagonists is passive Heymann
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nephritis (PHN), a model of in-situ immune-complex dis-
ease. Arai and colleagues investigated the effects of mani-
dipine and suggested that the renal protective mechanism
relates to favorable effects on lipid peroxidation [69].
Manidipine administration in rats with PHN attenuated the
increase in urinary albumin excretion and fractional clear-
ance of albumin. The researchers speculated that one of the
mechanisms by which manidipine lessens proteinuria in
PHN is attributable to the decrease in the accumulation of
lipid peroxidation products in the renal cortex [69].
In contrast to these studies, other investigators have
failed to demonstrate a beneficial effect of calcium antag-
onists in diverse experimental models of chronic renal
failure [70–72]. Brunner et al found that administration of
verapamil to rats with remnant kidneys exacerbated renal
injury and increased renal size [71]. However, treatment
was begun several weeks after renal ablation, after the
onset of hypertrophy and injury. Tolins and Raij compared
the calcium antagonist TA 3090 to enalapril in Dahl S rats
after 5⁄6 renal ablation and found that glomerular volume
was significantly reduced by the calcium antagonist when
compared with either control or enalapril-treated rats [72].
However, they reported that although enalapril prevented
glomerular sclerosis, the calcium antagonist only delayed
the onset of injury. The discrepancies might have resulted
from the use of the remnant model of chronic renal failure
in the Dahl S rat, a model of highly aggressive renal disease.
One possible explanation for the different results might
relate to the lack of equivalence of blood pressure control.
Clearly the interpretation of these studies as to the patho-
genetic role of hypertensive mechanisms depends on the
adequacy of periodic tail-cuff blood pressure measure-
ments to accurately assess the differences in systemic blood
pressure within and between groups. Recent studies by
Griffin et al using the radiotelemetric technique of contin-
uous blood pressure monitoring have demonstrated a
marked spontaneous lability of blood pressure in the
remnant kidney model [73, 74]. Such lability severely limits
the capacity of the tail-cuff method to accurately assess the
ambient systemic blood pressure profiles and, therefore, to
examine the relationship of glomeruloprotection to the
relative antihypertensive effectiveness of different antihy-
pertensive regimens. To obviate this problem, Griffin et al
utilized radiotelemetric blood pressure monitoring for 6
weeks to compare the effects of enalapril to nifedipine in
the rat 5⁄6 renal ablation model [73]. Glomerulosclerosis
was prevented by enalapril (2% 6 1% versus 26% 6 5% in
controls) but not by nifedipine (25% 6 6%). Glomerulo-
sclerosis correlated well with the overall averaged blood
pressure in individual animals of all groups, but the slope of
the relationship was significantly steeper in nifedipine-
treated compared with control and enalapril-treated rats (P
, 0.02); this result suggested greater pressure transmission
to the glomeruli and glomerulosclerosis for any given blood
pressure. Because autoregulatory mechanisms provide the
primary protection against pressure transmission, renal
autoregulation was examined at 3 weeks in an additional
group of rats. Autoregulation was impaired in control rats,
was not additionally altered by enalapril, but was com-
pletely abolished by nifedipine. These data demonstrate the
importance of autoregulatory mechanisms in the pathogen-
esis of hypertensive injury. The investigators suggested that
calcium antagonists, which adversely affect pressure trans-
missions, do not provide protection despite significant
blood pressure reduction [73]. Recent studies of protein
restriction support earlier work by these investigators [75].
Studies in rats with remnant kidneys placed on a low-
protein (LP) intake disclosed that autoregulation is the
critical component for LP-diet-conferred glomeruloprotec-
tion and that its impairment abrogates such protection
despite the maintenance of the LP-diet-induced inhibition
of growth responses.
Recently Picken et al used radiotelemetric systolic blood
pressure monitoring for 7 weeks to compare the relation-
ship between blood pressure reduction and glomeruloscle-
rosis for three different classes of calcium antagonists in the
remnant kidney model: diltiazem, verapamil, and felodip-
ine [76]. Excellent correlations were observed between
blood pressure and percentage of glomerulosclerosis in
each group (r 5 0.75 to 0.84, P , 0.01). These authors
utilized the slope of the relationship between blood pres-
sure and glomerulosclerosis as an index of the effect of
calcium-channel blockers on the glomerular transmission
of systemic blood pressure. This slope did not differ
between control and diltiazem-treated animals; verapamil
caused a modest shift to the left, while felodipine resulted
in both a shift to the left and in a markedly steeper slope,
suggesting a greater glomerular transmission of systemic
pressure. The adverse effects of the slope (felodipine .
verapamil) explain why glomeruloprotection was not
achieved with verapamil and felodipine despite blood pres-
sure reduction. The investigators interpreted the results as
suggesting that significant differences exist between calci-
um-channel blockers in their relative impact on systemic
blood pressure and on glomerulosclerosis because of their
different effects on renal vascular autoregulatory responses
[76].
In a recent editorial, Bidani and Griffin summarized the
results of many of these trials and concluded that the key to
these discrepancies lies in the interplay between the loss of
intrarenal autoregulation, which occurs with the adminis-
tration of calcium antagonists, and the magnitude of the
reduction in the blood pressure achieved [77]. Calcium
antagonists decrease the afferent arteriolar tone, allowing a
greater transmission of systemic blood pressure to the
glomerular capillaries. This effect in turn may be offset by
the ability of calcium antagonists to lower systemic blood
pressure, thereby causing no net change or even a reduc-
tion in the intraglomerular pressure.
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Clinical studies assessing the renoprotective effects of
calcium antagonists
Only recently have long-term clinical trials assessed the
renoprotective effects of calcium antagonists. Although few
in number, in concert the available studies suggest that
calcium antagonists are beneficial in stabilizing renal func-
tion. Zucchelli and colleagues reported the results of their
prospective, randomized controlled trial in which they
compared the effects of an ACE inhibitor, captopril, and a
dihydropyridine calcium antagonist, nifedipine, on both
hypertension and the progression of renal insufficiency
[78]. During the one-year pre-randomization period, pa-
tients were treated with various standard antihypertensive
combinations including b-blockers, furosemide, clonidine,
and hydralazine. Subsequently, 121 hypertensive patients
with chronic renal failure were randomly allocated to either
captopril or slow-release nifedipine treatment for a 3-year
period. The rate of progression of renal insufficiency,
assessed as 1/serum creatinine versus time, creatinine clear-
ance versus time, and 99mTC diethylenetriaminepenta-ace-
tic acid clearance versus time was attenuated to a similar
degree in both treatment groups. These investigators pro-
posed that their data were “consistent with the hypothesis
that both calcium antagonists and ACE inhibitors possess a
renoprotective effect.”
A number of events related to the experimental design
and the conduct of the study, however, raise questions
about this conclusion. First, because the mean arterial
pressure was higher during the pre-randomization period,
when treated with standard therapy, better control of blood
pressure might have contributed to the retardation of the
progression rate of renal insufficiency by both ACE inhib-
itors and calcium antagonists. Furthermore, the interpreta-
tion of the renal survival curves is fraught with difficulty. Of
the 121 patients who underwent randomization at the end
of the initial year of study, only 37 patients concluded 3
years of study in the captopril group, and only 32 patients
in the nifedipine group did. In the third year, 11 of the
remaining 46 patients in the nifedipine group and only 2 of
the remaining 44 patients in the captopril group reached
end-stage renal disease (P , 0.005). The reduction in
statistical power might account for the absence of a differ-
ence in overall renal survival between the two groups. The
resultant diminution in the number of patients during the
final year of study confounds interpretation of the renal
survival curves.
Subsequently, two studies in hypertensive diabetic pa-
tients have circumvented many of the methodologic con-
cerns of the Zucchelli study. Velussi et al compared the
effects of cilazapril versus amlodipine on GFR and albumin
excretion in hypertensive patients with non-insulin-depen-
dent diabetes mellitus (NIDDM) [79]. Twenty-six patients
had normoalbuminuria and 18 had microalbuminuria. Glo-
merular filtration rate was measured by plasma clearance of
51Cr EDTA at baseline and every 6 to 12 months during a
3-year followup interval. The GFR decline (mean 6 SE)
per year in the normoalbuminuric patients during cilazapril
treatment was similar to that observed during amlodipine
therapy. Furthermore the GFR decline per year in the
microalbuminuric patients during cilazapril therapy did not
differ from that observed with amlodipine. Cilazapril and
amlodipine lowered the albumin excretion rate to a similar
extent in normoalbuminuric and microalbuminuric pa-
tients.
In a recent carefully conducted study, Rossing et al
compared the effects of the long-acting dihydropyridine
nisoldipine with those of the ACE inhibitor lisinopril on
proteinuria and on decline in GFR in 49 hypertensive
patients with IDDM [80]. Interim results at the end of the
first year disclosed a striking dissociation between the
antiproteinuric effects and the effects on GFR. Albumin-
uria was reduced by 47% in the lisinopril group versus no
decrement in the nisoldipine group. In marked contrast,
the decline in GFR tended to be less steep in the nisoldip-
ine group compared with the decline in the lisinopril group.
Although the numbers are small, these observations sug-
gest that a dihydropyridine, presumably acting through
mechanisms independent of its renal microcirculatory ef-
fects, is renoprotective.
Campbell and colleagues recently reported on the results
of a large multicenter trial comparing the effects of ACE
inhibitors versus calcium antagonists in normotensive dia-
betic subjects (systolic blood pressure , 140 mm Hg if age
, 40, otherwise systolic blood pressure , 160 mm Hg, and
diastolic blood pressure , 90 mm Hg) with microprotein-
uria (albumin excretion rate, 20–200 mg/min) [81]. Subjects
were randomly assigned to receive placebo, perindopril, or
nifedipine. Perindopril (2–8 mg/day) and nifedipine (slow
release, 10–40 mg/day) were titrated to achieve a fall in
supine diastolic blood pressure . 4 mm Hg). Data for 2 to
7 years were obtained from 60 subjects. For patients with
IDDM, perindopril reduced the rate of change in albumin
excretion rate, but neither drug affected blood pressure or
rate of change in creatinine clearance. For patients with
NIDDM, although both drugs reduced blood pressure
similarly, neither drug affected the rate of change in
albumin excretion rate or creatinine clearance. The authors
concluded that reduction of proteinuria by antihypertensive
agents does not necessarily predict a reduced rate of
decline in creatinine clearance, and that protection of renal
function by these agents is determined in part by the
absolute blood pressure achieved.
In summary, although only relatively few studies are
available for review, and the numbers of patients are small,
their results suggest that calcium antagonists attenuate or
stabilize the progression of chronic renal failure. Clearly
more studies are needed to confirm this postulate.
A number of similar studies are underway to compare
the effects of therapy with an ACE inhibitor combined with
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a calcium antagonist versus either intervention alone in
patients with nondiabetic renal disease. Two years ago, a
large, randomized prospective study was initiated to assess
renal protection in nondiabetic renal disease. The Euro-
pean Multicenter Study on Progression in Nondiabetic
Renal Disease (NEPHROS study) will compare the renal
protective effects of ramipril, felodipine, or the combina-
tion of ramipril plus felodipine (personal communication).
Two hundred patients with nondiabetic renal disease will
be recruited in the United Kingdom, France, Germany,
Israel, and Sweden. A second study will soon be initiated
comparing the renal protective effects of trandolapril,
verapamil, or the combination of trandolapril plus vera-
pamil.
Do chemically dissimilar calcium antagonists differ in
their renal effects?
In addition to the question of whether calcium antago-
nists as a class are renoprotective, interest has focused on
the question of whether differences exist within the class,
for example, dihydropyridine versus nondihydropyridine
calcium antagonists. Maki et al conducted a meta-analysis
of investigations with followup times of at least 6 months to
assess the effects of different antihypertensive agents on
proteinuria and GFR in patients with renal disease [82].
They included studies in diabetic and nondiabetic patients
with renal disease. Analysis of the results of 14 randomized
controlled trials disclosed that ACE inhibitors caused a
greater decrease in proteinuria, improvement in GFR, and
decline in mean arterial pressure compared with controls.
In a multivariate analysis of controlled and uncontrolled
trials, each 10 mm Hg reduction in blood pressure de-
creased proteinuria, but ACE inhibitors and nondihydro-
pyridine calcium antagonists were associated with addi-
tional declines in proteinuria that were independent of
blood pressure changes and diabetes. Each 10 mm Hg
reduction in blood pressure caused a relative improvement
in glomerular filtration rate (0.18 ml/min/month), but in
diabetic patients dihydropyridine calcium antagonists
tended to cause a relative reduction in glomerular filtration
rate (20.68 ml/min/month). Maki and colleagues empha-
sized that the results of their retrospective analysis should
be interpreted with caution and proposed that direct long-
term comparison studies are needed to determine whether
class differences exist between ACE inhibitors and calcium
antagonists, and whether specific differences exist within
the classes.
Only one investigative group has demonstrated that
nondihydropyridine calcium antagonists confer a greater
renoprotective effect in randomized prospective studies.
Lash and Bakris conducted a 4-year followup study in
patients with nephropathy from type-II diabetes and ob-
served that therapy with lisinopril and verapamil reduces
nephrotic-range proteinuria. The combination of the two
agents induced a greater effect than did either agent alone
[83]. This benefit occurred in the absence of additional
antihypertensive effects of the combination.
It is too early for us to ascertain whether dihydropyri-
dines indeed differ from nondihydropyridines in their renal
effects. Clearly, additional long-term studies enrolling
larger numbers of patients are required to rigorously
compare the effects of chemically dissimilar calcium antag-
onists on proteinuria and on their ability to stabilize GFR.
Does it matter whether calcium antagonists are
renoprotective?
In light of the compelling data indicating that ACE
inhibitors are renoprotective in the clinical setting of
diabetes and hypertension, should we concern ourselves
with the possibility that calcium antagonists are also bene-
ficial? I believe we should. Recent reports have emphasized
that our failure to achieve blood pressure control is partly
attributable to a misplaced focus on monotherapy. Most
patients with renal insufficiency or diabetes require at least
two drugs for adequate blood pressure control. In fact a
report by Stefanski et al noted that their patients with
chronic renal insufficiency and severe hypertension require
more than four antihypertensive agents to control their
blood pressure [1]. These observations have been con-
firmed by recent data. Bakris et al reported that an average
of 4.3 antihypertensive medications were required by dia-
betic hypertensive patients to reduce blood pressure to
levels of , 130/80 mm Hg [2]. These findings underscore
the need to include in our antihypertensive armamentar-
ium not one but several antihypertensive agents that share
the attributes of efficacy, maintenance of metabolic neu-
trality, and the ability to stabilize renal function in the
setting of progressive renal disease.
An additional consideration that merits attention is how
ACE inhibitors differ from calcium antagonists in renal
potassium handling. The very patients (for example, dia-
betics or patients with progressive renal failure) who might
be suitable candidates for ACE inhibitor therapy (for
retarding progression of their disease) are the ones most
likely to develop hyperkalemia as a consequence. In con-
trast, calcium antagonists do not provoke hyperkalemia.
Indeed, studies by Solomon et al in subjects with end-stage
renal disease have suggested that the benzothiazepine
diltiazem enhances potassium disposal [84]. Consequently,
patients who tend to develop hyperkalemia when treated
with ACE inhibitors might benefit from calcium antagonists
because these agents do not increase plasma potassium
levels.
Critique of the ABCD and FACET studies and
concluding remarks
Increasing evidence indicates a need for more rigorous
blood pressure control in the hypertensive diabetic patient.
Although much attention has focused on the renal protec-
tive attributes of ACE inhibitors, the side effects of this
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drug class render ACE inhibitors inappropriate for some
diabetic patients. Furthermore, it is becoming increasingly
apparent that appropriate blood pressure control in the
diabetic hypertensive patient frequently requires more than
one class of antihypertensive drugs. Recent studies have
focused on identifying appropriate antihypertensive agents
that not only lower blood pressure but also retard the
progression of renal disease.
These considerations have focused our attention on
calcium antagonists and their effects on renal function and
renal hemodynamics. In addition to their efficacy and
maintenance of metabolic neutrality, recent preliminary
reports suggest that, despite their renal microcirculatory
effects, some calcium antagonists can slow progressive
renal failure. Such considerations have prompted the initi-
ation of several randomized, prospective, long-term studies
to elucidate the renoprotective effects of monotherapy with
calcium antagonists. It is becoming apparent that several
pharmacologic interventions may be capable of retarding
the progression of renal failure.
In light of these considerations, the recent report of the
ABCD trial [85] warrants consideration and discussion as
to whether it militates against the use of calcium antago-
nists in diabetic patients with hypertension. The ABCD
trial, still underway at the University of Colorado Life
Sciences Center, is a prospective, 5-year, randomized,
double-blind study scheduled to end in June 1998. The
study is designed to evaluate the effects of intensive versus
moderate blood pressure control on the prevention or
progression of non-insulin-dependent diabetes mellitus
(NIDDM) nephropathy, neuropathy, retinopathy and car-
diovascular events in 950 patients. A secondary objective of
this trial is to evaluate the effects of a long-acting calcium
antagonist, nisoldipine, and an ACE inhibitor, enalapril, as
first-line antihypertensive agents in the prevention and
progression of diabetic vascular complications. In this
population of patients with diabetes and hypertension, the
authors found a significantly higher incidence of fatal and
nonfatal myocardial infarction among those assigned to
therapy with the calcium-antagonist nisoldipine than
among those assigned to receive enalapril.
As the authors rightfully acknowledge, the findings are
based on a secondary end point, and therefore require
confirmation [85]. Although patients who received the
calcium antagonist had a significantly higher rate of nonfa-
tal myocardial infarction than did those receiving the
angiotensin-converting-enzyme inhibitor, the incidence of
other cardiovascular events did not differ between the
patients taking a calcium antagonist and those treated with
an ACE inhibitor. Specifically, cerebrovascular accidents,
congestive heart failure, and death from cardiovascular
causes did not significantly differ between these groups. In
fact, death from any cause was not statistically significantly
different (nisoldipine 5 17; enalapril 5 13). Furthermore,
the study failed to distinguish between a deleterious effect
of nisoldipine, a protective effect of enalapril, or a combi-
nation of both as a reason for the difference observed.
Although comparisons with historic controls are not ideal,
it is interesting to note that the rate of myocardial infarc-
tion among patients with NIDDM who were randomly
assigned to therapy with nisoldipine in the study is not
significantly different from that in other recent studies of
patients with NIDDM [86, 87]. This observation suggests
that the findings resulted from a protective effect of the
ACE inhibitor. Although the ABCD study cannot distin-
guish among these possibilities, the ongoing ALLHAT
study [88] should allow us to elucidate the reason for the
results reported. Because there are more than two drug-
treatment goups, it should be possible to distinguish harm
from benefit if differences in end-point rates are observed
in the future, since a treatment with known benefit in terms
of cardiovascular outcomes—a diuretic—is included.
Unfortunately, many physicians have assumed that the
adverse effects attributed to nisoldipine are reflective of the
calcium antagonist class as a whole and have extrapolated
inappropriately these effects to drugs with more advanced
extended release formulations [89, 90] or drugs that are
intrinsically long acting (amlodipine, lacidipine) that have a
markedly different pharmacokinetic profile. Indeed, a re-
view of the few available data suggests a theoretic frame-
work for anticipating that these pharmacokinetic differ-
ences may be exaggerated in the setting of diabetes mellitus
(Epstein M, Preston R, unpublished observations). Ampli-
fication of such differences in the diabetic patient could
explain differences in clinical efficacy as well as adverse
cardiovascular events.
Another study that has recently stirred the waters is the
FACET study. For purposes of this discussion, I have
elected to analyze and critique the FACET study because it
exemplifies some of the problems, inconsistencies, and
indeed lack of rigor that confound some recent reports.
Unfortunately, many clinicians fail to take the time neces-
sary to critically review such reports, and therefore they
arrive at misleading conclusions.
The recent Fosinopril Versus Amlodipine Cardiovascu-
lar Events Randomized Trial (FACET) [91] adds addi-
tional fuel to the fire regarding a possible adverse effect of
calcium antagonists. The FACET study compared the
effects of fosinopril and amlodipine on serum lipids and
diabetes control in NIDDM patients with hypertension.
Prospectively defined cardiovascular events were assessed
as secondary outcomes. A total of 380 hypertensive diabet-
ics were randomly assigned to open-label fosinopril (20
mg/day) or amlodipine (10 mg/day) and followed for as
long as 3.5 years. If blood pressure was not controlled, the
other study drug was added. Both treatments were effective
in lowering blood pressure. At the end of followup, the two
groups had no significant difference in total serum lipids or
glycemic control. The patients receiving fosinopril had a
significantly lower risk of the combined outcome of acute
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myocardial infarction, stroke, or hospitalization for angina
than did the patients receiving amlodipine (14/189 versus
27/191; hazards ratio 5 0.49).
Various factors related to the experimental design and
the conduct of the study confound the certainty of this
conclusion, however. First, a number of key aspects of the
study have changed since the original abstract was pub-
lished in 1996. Of note, the original abstract concluded that
the combination of amlodipine and fosinopril provided the
best outcomes for diabetic hypertensive patients [92]. This
group was composed entirely of subjects who had failed one
of the randomized monotherapies, and so might be pre-
sumed to have been at higher risk. In contrast, the newly
published material now concludes that the ACE inhibitor is
superior to the calcium antagonist [91]. In addition, the
number of patients assigned to each study group has
changed. In the first 6 months post randomization, the
amlodipine group had 20 dropouts and 50 crossovers (to
amlodipine 1 fosinopril), whereas the fosinopril group had
13 dropouts and 60 crossovers. Thus, 70/190 (37%) and
76/190 (40%) were no longer in their randomized groups by
June 1993, 6 months after recruitment ended (and the
starting point for followup in the original trial). It is also
important to note that this is an open-label, single-center
study, which exposes the results to sponsor and investigator
bias [91]. Finally, and perhaps most important, there were
no significant differences between the study groups for any
of the individual cardiovascular events, and all-cause mor-
tality was the same for the amlodipine and fosinopril
groups. Only when various events were arbitrarily grouped
together did any of the events reach statistical significance
[91].
Until the ongoing morbidity and mortality studies with
calcium antagonists such as ALLHAT establish definitively
what the effects of calcium antagonists are on cardiovascu-
lar risk, what should physicians do? The available evidence
is clear that ACE inhibitors should be used as initial
monotherapy in managing the diabetic hypertensive pa-
tient. Nesto and Zarich recently summarized the evidence
indicating that ACE inhibitors can be helpful in the dia-
betic patient with cardiovascular disease [93]. Experimental
data indicate that ACE inhibitors can suppress plasmino-
gen activator expression and improve fibrinolytic capacity
in patients after MI [93]. Also, ACE inhibitors markedly
improve insulin sensitivity and glycemic control. Because
improved glycemic control is associated with improved
mortality after MI in diabetic patients receiving insulin [93],
ACE inhibitors might improve survival in this group by
concomitantly decreasing insulin resistance, improving gly-
cemic control, and restoring fibrinolytic capacity. The data
are even more compelling with respect to renal protection.
Randomized prospective studies have shown that ACE
inhibitors clearly confer benefits beyond those of blood
pressure reduction. However, as I have said, monotherapy
with ACE inhibitors often does not suffice to achieve the
new target blood pressures advocated by the Joint National
Commission VI. In such settings I believe it is prudent to
add a calcium antagonist as a second agent because of its
efficacy, metabolic neutrality, and the fact that its mecha-
nisms of action complement those of ACE inhibitors.
QUESTIONS AND ANSWERS
DR. NICOLAOS E. MADIAS (Chief, Division of Nephrology,
New England Medical Center, Boston, Massachusetts): Could
you please expand on the issue of whether calcium antag-
onists of different molecular structure differ in terms of
their effects on the kidney?
DR. EPSTEIN: Yes, that is a key point. Clearly, there are
differences on the renal microcirculatory profile, as I noted.
Efonidipine and manidipine appear to have a greater
efferent vasodilatory effect than do the traditional drugs
verapamil or diltiazem. The second issue, and I think the
most relevant one, is whether chemically dissimilar calcium
antagonists differ in their effects on proteinuria and stabi-
lization of renal function. We don’t know about stabiliza-
tion of renal function, but some newer data have suggested
that some of the nondihydropyridines have a greater ben-
eficial effect. Most of these studies stem primarily from one
group, Bakris and colleagues, who in a series of recent
publications have suggested that verapamil or diltiazem
appears to have a greater effect in terms of diminishing
proteinuria over the period of observation [2, 94]. It’s an
intriguing observation that requires confirmation by other
investigators in other laboratories, but if it’s true, and I
have no reason to doubt that it is, it raises an important
issue as to what the mechanisms are. The renal microcir-
culatory profile of verapamil and diltiazem is similar to that
of most dihydropyridines. Thus the possibility exists that
non-hemodynamic mechanisms account for the greater
antiproteinuric affect.
DR. MADIAS: The antiproteinuric effect of ACE inhibi-
tors evolves over a period of weeks and appears to reflect
hemodynamic changes as well as changes in the permselec-
tive properties of the glomerular basement membrane.
Also, the antiproteinuric effect is potentiated by sodium
restriction or diuretics. Could you please comment on
whether there are similar observations regarding the anti-
proteinuric effect of calcium antagonists?
DR. EPSTEIN: It is well established that the ability of ACE
inhibitors to reduce albumin excretion depends on sodium
intake [95]. In contrast, relatively few studies have investi-
gated the effect of sodium intake on albuminuria in the
presence of calcium antagonist administration. Bakris and
Smith conducted a prospective, crossover, open-labeled
trial to determine whether sodium intake alters albumin
excretion in NIDDM patients with diabetic nephropathy
[94]. They compared the effects of once-daily diltiazem
with once-daily nifedipine to decrease blood pressure to
less than 140/90 mm Hg. A diet of 50 mEq of sodium per
day in combination with once-daily diltiazem reduced
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albumin excretion. Albumin excretion was not reduced
after a similar period of blood pressure reduction with
once-daily nifedipine. Although these observations must be
viewed with caution because of the non-randomized study
design and small number of patients, these authors suggest
that sodium restriction enhances the antiproteinuric effect
of some calcium antagonists.
Recently, Smith et al investigated the effects of chemi-
cally dissimilar calcium antagonists on glomerular perme-
ability [96]. They randomized 28 patients with type-II
diabetes to treatment with either diltiazem CD or nifedi-
pine GITS and assessed changes in glomerular permeabil-
ity using dextran clearances. At similar levels of blood
pressure (goal of mean blood pressure , 107 mm Hg),
diltiazem significantly reduced proteinuria by decreasing
glomerular membrane permeability, whereas nifedipine did
not. Additional studies must be conducted to further clarify
these interesting effects.
DR. JOHN T. HARRINGTON (Dean, Tufts University School
of Medicine, Boston): Murray, you discussed many of the
clinical studies, either published or in progress, but you had
concerns about several of them. How would you define the
ideal study of the renoprotective effects of calcium antag-
onists? Has that ideal study yet been done?
DR. EPSTEIN: The earlier concerns that I had about some
of those studies were related to duration—that the studies
were not of sufficient duration to allow us to make reason-
able inferences. Some were one to 2 years long, but I think
that optimally 4 to 5 years of followup are required. Many
studies have relied on very crude measures of renal func-
tion, serum creatinine concentration or creatinine clear-
ance, which certainly are not adequate, especially in pa-
tients with diabetic nephropathy. I believe some other
marker that would pass scrutiny must be used.
DR. HARRINGTON: You mentioned in passing that calcium
antagonists reduce renal cortical calcium content. How do
they do that? What’s the mechanism for that protective
effect? Do we know?
DR. EPSTEIN: I don’t know. Interestingly, that study by
Goligorsky was published in 1985. I’m unaware whether
anyone has confirmed or extended those initial observa-
tions in the 13 years since that study was published.
DR. ANDREW J. KING (Division of Nephrology, New En-
gland Medical Center): The antihypertensive effects of
calcium-channel blockers have been purported to be
greater in volume-expanded patients, including those with
end-stage renal disease. Could you speculate on the mech-
anisms involved in their response?
DR. EPSTEIN: The effects of most antihypertensive agents
are potentiated by a reduction in salt intake, and their
blood-pressure-lowering effect is blunted by a high salt
intake. The Blaustein hypothesis predicts that a high salt
intake will increase intracellular calcium [97]. This raises
the possibility that calcium antagonists are more effective
with patients on a high-salt intake. Cappuccio et al assessed
the effects of a normal-sodium intake (150 mEq/day) and a
high-sodium intake (350 mEq/day) on the blood pressure
response to a single capsule of nifedipine [98]. The differ-
ence in blood pressure between subjects taking a placebo
and those taking nifedipine was greater on the high-sodium
diet than on the low-sodium diet, but this difference failed
to reach statistical significance.
Studies with verapamil also have shown that the blood
pressure fall tends to be amplified on a high-sodium intake
[99]. The finding, therefore, that a high-sodium intake
appears at the very least not to blunt, and possibly en-
hances, the effect of the calcium antagonists is of interest.
I am not aware of subsequent studies that have extended
these earlier observations, however.
DR. KING: Could you comment on the relative antihyper-
tensive effectiveness of the various classes of calcium-
channel antagonists?
DR. EPSTEIN: Generally, the dihydropyridines are more
effective. But this issue is broader than mere differences in
the chemical structure. I’m an advocate for drug formula-
tion as a determinant of clinical decision-making. Specifi-
cally, clinical experience has demonstrated that once-a-day
formulations dramatically change these drugs’ effects. This
was beautifully exemplified by a study a few years ago by
Kleinbloesem et al [100]. If one alters the rapidity of
attainment of a plasma concentration of nifedipine, that is,
rapid versus slow and gradual attainment, the effect on
heart rate and blood pressure is dramatically different.
Whereas a slow infusion of nifedipine lowered blood
pressure and caused no appreciable change in heart rate,
rapid intravenous infusion barely decreased blood pressure
but markedly raised heart rate. I am less concerned about
which dihydropyridine than I am by differences in formu-
lation. That is, I favor a drug that is taken once a day and
that acts over the entire 24-hour period. The concerns that
I’ve raised—the Griffen-Bidani studies, the studies from
Milan—all suggest that if we don’t control blood pressure
throughout the 24-hour period in a sustained manner, then
we fail to treat our patient optimally [101].
DR. MADIAS: Cyclosporine A is primarily an afferent
arteriole constrictor and, as you noted, calcium antagonists
are afferent arteriole dilators. Could you please address the
existing information on the effects of calcium antagonists
on the vasoconstrictive and nephrotoxic effects of cyclo-
sporine A?
DR. EPSTEIN: I earlier depicted data from some studies in
cadaveric kidney transplant recipients to make the point
that these agents may have utility in acute prophylaxis in
that setting. Another major area that has attracted a lot of
investigative attention is cyclosporine and its acute renal
vasoconstrictive effects. There is a clear-cut rationale for
why calcium antagonists act as renal vasodilators in this
setting. Thromboxane mimetics induce afferent arteriolar
constriction, and we have reported that calcium antagonists
can reverse this constriction in a dose-dependent manner
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[17]. Furthermore, endothelin induces afferent arteriolar
constriction and calcium antagonists can reverse that effect
as well [16]. To the extent that both of these are thought to
constitute important mediators of cyclosporine-induced
vasoconstriction, it is reasonable to anticipate that calcium
antagonists would be able to reverse the renal vasoconstric-
tion. Indeed, this has been reported by Ruggenenti and
colleagues in Italy [102] and by other investigators [103,
104].
DR. HARRINGTON: You showed a difference in blood
pressure, monitored radiotelemetrically, between enalapril
and nifedipine. Was that difference related to nifedipine
per se or to a specific formulation of nifedipine? Shouldn’t
we be able to obtain the same results with nifedipine as with
enalapril?
DR. EPSTEIN: In that instance, we are looking at the
chemical agent per se and not formulation, because nifed-
ipine in the GITS formulation cannot be administered to
laboratory animals. When the GITS formulation of nifed-
ipine is administered to patients, much of the variability in
that study is dramatically attenuated clinically by the ad-
ministration of appropriate long-acting formulations or by
drugs that are intrinsically long-acting, such as amlodipine
or lacidipine (available in Europe but not available in the
United States).
DR. ANDREW S. LEVEY (Division of Nephrology, New
England Medical Center): Thank you very much for a
balanced view of calcium-channel blockers in retarding the
progression of renal disease. Most recent clinical trials that
demonstrate the usefulness of ACE inhibitors in slowing
the progression of diabetic or non-diabetic nephropathy
have not been “head-to-head” comparisons with calcium-
channel blockers. What clinical trial design do you favor for
comparing these agents? Specifically, do you believe it is
proper to omit an ACE inhibitor from the treatment of
patients with progressive renal disease for the purpose of
determining whether other agents are equally efficacious?
DR. EPSTEIN: As I noted previously, I believe the most
important intervention for retarding progression of renal
disease is adequate and sustained blood-pressure lowering.
Once we attain that goal, a secondary issue is whether some
antihypertensive classes preferentially confer additional
renal protection. I agree with you that recent studies have
documented that ACE inhibitors are especially efficacious
in retarding progressive renal disease. The data with re-
spect to calcium antagonists are suggestive but inconsistent.
Although I believe that comparisons of ACE inhibitors
versus calcium antagonists are acceptable in disorders
other than type-I diabetes mellitus, physicians are unlikely
to allow their patients to be randomized to a non-ACE-
inhibitor treatment arm. Consequently, an alternative study
approach should be considered. In light of recent reports
indicating that monotherapy is often inadequate for lower-
ing blood pressure in many of these patients, a reasonable
approach might be to compare ACE inhibitors plus diuret-
ics versus ACE inhibitors plus calcium antagonists. This
comparison will allow us to discern whether calcium antag-
onists are equally or more renoprotective than other agents
at similar levels of blood-pressure reduction.
Reprint requests to Dr. M. Epstein, Nephrology Section, VA Medical
Center, 1201 NW 16th Street, Miami, Florida 33125, USA
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